Compare Piramal Healthcare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs GLENMARK PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES GLENMARK PHARMA PIRAMAL ENTERPRISES/
GLENMARK PHARMA
 
P/E (TTM) x 13.7 10.1 136.3% View Chart
P/BV x 0.9 1.4 60.6% View Chart
Dividend Yield % 2.0 0.7 290.7%  

Financials

 PIRAMAL ENTERPRISES   GLENMARK PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
GLENMARK PHARMA
Mar-19
PIRAMAL ENTERPRISES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,303712 464.1%   
Low Rs1,797484 371.5%   
Sales per share (Unadj.) Rs716.5349.6 204.9%  
Earnings per share (Unadj.) Rs79.732.8 243.1%  
Cash flow per share (Unadj.) Rs107.944.3 243.4%  
Dividends per share (Unadj.) Rs28.002.00 1,400.0%  
Dividend yield (eoy) %1.10.3 328.1%  
Book value per share (Unadj.) Rs1,477.5198.6 743.8%  
Shares outstanding (eoy) m184.45282.17 65.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.61.7 208.2%   
Avg P/E ratio x32.018.2 175.5%  
P/CF ratio (eoy) x23.613.5 175.3%  
Price / Book Value ratio x1.73.0 57.4%  
Dividend payout %35.16.1 575.8%   
Avg Mkt Cap Rs m470,292168,625 278.9%   
No. of employees `0007.812.0 65.0%   
Total wages/salary Rs m22,50420,561 109.4%   
Avg. sales/employee Rs Th16,899.48,196.0 206.2%   
Avg. wages/employee Rs Th2,877.71,708.1 168.5%   
Avg. net profit/employee Rs Th1,879.9768.5 244.6%   
INCOME DATA
Net Sales Rs m132,15398,655 134.0%  
Other income Rs m3,1282,081 150.3%   
Total revenues Rs m135,281100,736 134.3%   
Gross profit Rs m66,29015,858 418.0%  
Depreciation Rs m5,2023,259 159.6%   
Interest Rs m44,0973,346 1,318.0%   
Profit before tax Rs m20,11911,335 177.5%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m8,6113,756 229.2%   
Profit after tax Rs m14,7019,250 158.9%  
Gross profit margin %50.216.1 312.1%  
Effective tax rate %42.833.1 129.2%   
Net profit margin %11.19.4 118.6%  
BALANCE SHEET DATA
Current assets Rs m122,74266,968 183.3%   
Current liabilities Rs m310,81040,211 772.9%   
Net working cap to sales %-142.327.1 -524.7%  
Current ratio x0.41.7 23.7%  
Inventory Days Days2383 27.7%  
Debtors Days Days3981 47.8%  
Net fixed assets Rs m116,90433,322 350.8%   
Share capital Rs m369282 130.7%   
"Free" reserves Rs m272,16155,770 488.0%   
Net worth Rs m272,53056,052 486.2%   
Long term debt Rs m270,19635,738 756.1%   
Total assets Rs m856,261132,888 644.3%  
Interest coverage x1.54.4 33.2%   
Debt to equity ratio x1.00.6 155.5%  
Sales to assets ratio x0.20.7 20.8%   
Return on assets %6.99.5 72.4%  
Return on equity %5.416.5 32.7%  
Return on capital %12.417.8 69.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20062,998 24.1%   
Fx outflow Rs m4,88922,859 21.4%   
Net fx Rs m10,31240,140 25.7%   
CASH FLOW
From Operations Rs m-115,97513,242 -875.8%  
From Investments Rs m-8,265-6,990 118.2%  
From Financial Activity Rs m107,525-7,387 -1,455.5%  
Net Cashflow Rs m-16,650-2,971 560.5%  

Share Holding

Indian Promoters % 52.9 48.3 109.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 6.9 58.0%  
FIIs % 26.6 34.4 77.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.5 157.1%  
Shareholders   93,274 56,727 164.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   WYETH LTD  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 16, 2019 12:41 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS